Latest Content

Diane Stanaway, MSN, RN, highlights the importance of long-term skin protection for oncology patients during high-exposure events like the World Cup.

Nicholas Hornstein, MD, PhD discusses ctDNA in colorectal cancer, the INTERCEPT-TT trial, building Northwell's GI oncology program, and what better drugs will look like.

FDA approves sacituzumab govitecan-hziy as monotherapy and with pembrolizumab for first-line treatment of advanced triple-negative breast cancer.

The FDA approved palbociclib (Ibrance) for maintenance in HR+/HER2+ metastatic breast cancer after induction therapy, based on the PATINA trial.

Dr. Sriram Machineni explains why GLP-1 medications help manage cardiovascular health and inflammation in breast cancer survivorship.

Christina Klawitter explores the evolving role of oncology research nurses, highlighting the importance of pre-planning and interdisciplinary teamwork.

Teddi Mellencamp highlights the vital bond and advocacy of oncology nurses during the 2026 Extraordinary Healer awards ceremony in San Antonio.

Oncology nurses can guide patients through the rationale and implications of this decision.

Christina Klawitter, MSN, RN, OCN, discusses how meticulous pre-planning and team delegation optimize safety and patient care in clinical trials.

Dan Silver, PA-C, discusses the importance of early intervention in penile rehabilitation and the APP’s role as a partner in prostate cancer recovery.

ASCO warns oncology nurses of the risks of ivermectin and fenbendazole, urging proactive patient communication and monitoring of alternative therapies.

MSK researchers report that daraxonrasib, a breakthrough KRAS-targeted drug, nearly doubles survival time and improves quality of life for patients.

ASCO 2026 data show daraxonrasib doubles survival in pancreatic cancer. MSK’s Mary Larsen discusses oral adherence and managing signature side effects.